Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Moronic acid resistant to (bevirimat). This derivative has become a new lead for clinical trials and is also active against herpes simplex virus 1. Moronic acid Moronic acid (3-oxoolean-18-en-28-oic acid) is a natural triterpene. Moronic acid can be extracted from "Rhus javanica", a sumac plant traditionally believed to hold medicinal applications. The molecule has also been extracted from Mistletoe ("Phoradendron reichenbachianum"). Bevirimat, a derivative of the related triterpenoid betulinic acid, is under development as an anti-HIV drug; however, moronic acid has shown better antiviral profiles "in vitro" than bevirimat. A particular moronic acid derivative showed potent anti-HIV activity with EC values of